0001213900-23-069028.txt : 20230818 0001213900-23-069028.hdr.sgml : 20230818 20230818170550 ACCESSION NUMBER: 0001213900-23-069028 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230630 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230818 DATE AS OF CHANGE: 20230818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ADIAL PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001513525 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 800667150 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38323 FILM NUMBER: 231186606 BUSINESS ADDRESS: STREET 1: 1180 SEMINOLE TRAIL STREET 2: SUITE 495 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22901 BUSINESS PHONE: 434-422-9800 MAIL ADDRESS: STREET 1: 1180 SEMINOLE TRAIL STREET 2: SUITE 495 CITY: CHARLOTTESVILLE STATE: VA ZIP: 22901 FORMER COMPANY: FORMER CONFORMED NAME: ADial Pharmaceuticals, L.L.C. DATE OF NAME CHANGE: 20170515 FORMER COMPANY: FORMER CONFORMED NAME: Adial Pharmaceuticals, L.L.C. DATE OF NAME CHANGE: 20110218 8-K 1 ea183898-8k_adialpharm.htm CURRENT REPORT
0001513525 false 0001513525 2023-06-30 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (date of earliest event reported): June 30, 2023

 

Adial Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

 

Delaware   001-38323   82-3074668
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

 

1180 Seminole Trail, Ste 495
Charlottesville, VA 22901

(Address of principal executive offices and zip code)

 

(434) 422-9800

(Registrant’s telephone number including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

  Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbols   Name of each exchange on which registered
Common Stock   ADIL   The Nasdaq Stock Market LLC
(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.01 Completion of Acquisition or Disposition of Assets.

 

Adial Pharmaceuticals, Inc. (the “Company”) completed the sale of the assets and business of Purnovate, Inc. (“Purnovate”) to Adovate, LLC (formerly known as Adenomed, LLC) (collectively, “Adovate”) under that certain Option Agreement for the Acquisition of Purnovate, Inc. by Adenomed, LLC, dated as of January 27, 2023 (the “Option Agreement”), and related Option Exercise Agreement, dated May 8, 2023 (the “Option Exercise Agreement”), effective June 30, 2023.

 

This Form 8-K is being filed to provide the pro forma financial information required by Item 9.01(b) of Form 8-K.

 

Pursuant to the Option Agreement and Option Exercise Agreement, in consideration for the sale to Adovate of the assets and business of Purnovate: (i) the Company received a non-refundable option exercise fee and upfront payment of $450,000; (ii) Adovate will reimburse all approved Purnovate expenditures incurred and paid commencing December 1, 2022 through and including May 15, 2023, (iii) Adovate issued to the Company of 19.99% of the equity of Adovate; (iv) Adovate assumed the obligations of Company under that certain Equity Purchase Agreement by and among Company, Purnovate, the members of Purnovate, and Robert D. Thompson as the member’s representative, dated December 7, 2020 and amended January 25, 2021 (the “PNV EPA”); (v) Adovate assumed the Company’s obligations under that certain Employment Agreement, dated July 31, 2018, as amended, by and between Company and William Stilley; and (vi) the Company will receive low, single digit royalty payments on net sales, cash payments of up to approximately $11 million in development and approval milestones for each compound after payments to the prior members of Purnovate pursuant to the PNV EPA and cash payments of up to an aggregate of $50,000,000 upon the achievement of certain commercial milestones.

 

The foregoing summaries of the Option Agreement and Option Exercise Agreement do not purport to be complete and are subject to and are qualified in their entirety by reference to the full text of such documents attached as Exhibits 2.1 and 2.2, respectively, to this Current Report on Form 8-K, which are incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)Exhibits.

 

Exhibit No.   Description

2.1

 

   Option Agreement for the Acquisition of Purnovate, Inc. by Adenomed, LLC, dated as of January 27, 2023 (incorporated by reference Exhibit 2.1 to the Current Report on Form 8-K as filed by the Registrant with the Securities and Exchange Commission on February 1, 2023 (File No. 001-38323)
2.2   Option Exercise Agreement, dated May 8, 2023, by and between Adovate LLC and Adial Pharmaceuticals, Inc. (incorporated by reference Exhibit 2.2 to the Current Report on Form 8-K as filed by the Registrant with the Securities and Exchange Commission on May 10, 2023 (File No. 001-38323)

99.1

 

   Unaudited Pro Forma Condensed Consolidated Balance Sheet as of March 31, 2023; Unaudited Pro Forma Condensed Statements of Operations for the Three Months Ended March 31, 2023; and Unaudited Pro Forma Condensed Statements of Operations for the Year Ended Ended December 31, 2022
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* * * 

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: August 18, 2023 ADIAL PHARMACEUTICALS, INC.
   
  By:  /s/ Cary J. Claiborne
  Name:  Cary J. Claiborne                  
  Title: President and Chief Executive Officer

 

 

2 

 

 EX-99.1 2 ea183898ex99-1_adialpharm.htm UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET AS OF MARCH 31, 2023; UNAUDITED PRO FORMA CONDENSED STATEMENTS OF OPERATIONS FOR THE THREE MONTHS ENDED MARCH 31, 2023; AND UNAUDITED PRO FORMA CONDENSED STATEMENTS OF OPERATIONS FOR THE YEAR ENDED

Exhibit 99.1

 

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

 

The following unaudited pro forma condensed consolidated balance sheet and statements of operations are based upon the historical consolidated financial statements of Adial Pharmaceuticals, Inc. (the “Company”). Unless the context indicates otherwise, any reference in this report to the “Company,” “we,” “us,” and “our” refers to Adial Pharmaceuticals, Inc. The unaudited pro forma condensed consolidated financial statements have been prepared to illustrate the effect of the sale by the Company of the business of the Company’s wholly owned subsidiary, Purnovate, Inc. (the “Purnovate Sale”) for consideration including: (i) upfront cash payments totaling $450,000 upon the Option exercise; (ii) the issuance by Buyer to Company of 19.9% of the equity of Buyer; (iii) the assumption by Buyer of contingent payments due the former shareholders of Purnovate, Inc.; (iv) the assumption by Buyer of the obligations of Company to contracted Purnovate employees; (v) low, single digit royalty payment on net sales of all Purnovate products; (vi) contingent cash payments of up to approximately $11 million based on the achievement in development and approval milestones for the each Purnovate compound to reach the milestones after payments to the prior members of Purnovate pursuant to the Company’s previous agreement with the prior members of Purnovate for the Purchase of Purnovate; (vii) contingent cash payments of up to an aggregate of $50,000,000 upon the achievement of certain commercial milestones by the Buyer; and (viii) cash reimbursement of Purnovate expenses incurred and paid from Dec. 1, 2022 to the option exercise date of May 16, 2023. The Buyer also assumed liabilities of Purnovate, including: (i) trade payables incurred for services or purchases by Purnovate exclusively for its research operations; and (ii) the lease for 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901.

 

The unaudited pro forma condensed consolidated balance sheet as of March 31, 2023 reflects the pro forma effect as if the Purnovate Sale had been consummated on March 31, 2023. The unaudited pro forma condensed consolidated statements of operations for the three months ended March 31, 2023 and the year ended December 31, 2022 include the Company’s historical consolidated statements of operations adjusted to reflect the pro forma effect as if the Purnovate Sale had been effective January 1, 2022 (the first day of our 2022 fiscal year). The historical consolidated financial statements referred to above for the Company were included in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 and Annual Report on Form 10-K for the year ended December 31, 2022. The accompanying unaudited pro forma condensed consolidated financial information and the historical consolidated financial information presented herein should be read in conjunction with the historical consolidated financial statements and notes thereto.

 

The unaudited pro forma condensed consolidated balance sheet and statements of operations include pro forma adjustments which reflect transactions and events that (a) are directly attributable to the Sale, (b) are factually supportable and (c) with respect to the statement of operations, have a continuing impact on consolidated results. The pro forma adjustments are described in the accompanying notes to the unaudited pro forma condensed consolidated financial statements.

 

The unaudited pro forma condensed consolidated financial information does not reflect future events that may occur after the Sale, including potential general and administrative cost savings. The unaudited pro forma condensed consolidated statements of operations are provided for informational purposes only and are not necessarily indicative of the results of operations that would have occurred if the Purnovate Sale had occurred on January 1, 2022 nor is it necessarily indicative of our future operating results. The pro forma adjustments are subject to change and are based upon currently available information.

 

On August 4, 2023, the Company effected a reverse stock split of its outstanding shares of common stock, trading on Nasdaq under the symbol ADIL, at a ratio of 1-for-25. All references to common stock, stock warrants to purchase common stock, stock options to purchase common stock, share data, per share data and related information contained in these unaudited pro forma condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented.

 

 

 

 

ADIAL PHARMACEUTICALS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEETS

March 31, 2023

 

       Pro Forma         
   Historical   Adjustments       Pro Forma 
ASSETS
Current Assets:                
Cash and cash equivalents  $2,312,594   $450,000   (a)   $2,762,594 
Prepaid research and development   428,700    (428,700)  (b)    — 
Prepaid expenses and other current assets   223,356    —        223,356 
Asset payment receivable   —    757,390   (c)    757,390 
Total Current Assets   2,964,650    778,690        3,743,340 
                    
Fixed assets, net   48,492    (48,492)  (d)    — 
Intangible assets, net   4,336    —        4,336 
Acquired in-process research and development   455,000    (455,000)  (e)    — 
Right-to-use Asset   180,229    (180,229)  (f)    — 
Goodwill   248,971    (248,971)  (g)    — 
Equity method investment   —    1,727,897   (h)    1,727,897 
Total Assets  $3,901,678   $1,573,895       $5,475,573 
                    
LIABILITIES AND STOCKHOLDERS’ EQUITY                   
Current Liabilities:                   
Accounts payable  $530,141    (167,364)  (i)    362,777 
Accrued expenses   1,184,338    (37,290)  (j)    1,147,048 
Accrued expenses, related party   21,020    —        21,020 
Lease liability, current   58,751    (58,751)  (k)    — 
Other current liabilities   3,638    —        3,638 
Total Current Liabilities   1,797,888    (263,405)       1,534,483 
                    
Long-term Liabilities:                   
Contingent liabilities   506,000    (506,000)  (l)    — 
Lease liability, non-current   135,045    (135,045)  (k)    — 
Deferred tax liability   22,897    (21,382)  (m)    1,515 
Total Liabilities  $2,461,830   $(925,832)      $1,535,998 
                    
Stockholders’ Equity                   
Preferred Stock, 5,000,000 shares authorized with a par value of $0.001 per share, 0 shares outstanding at March 31, 2023   —    —        — 
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 1, shares issued and outstanding at March 31, 2023   1,140    —        1,140 
Additional paid in capital   68,019,075    —        68,019,075 
Accumulated deficit   (66,580,367)   2,499,727   (n)    (64,080,640)
Total Stockholders’ Equity   1,439,848    2,499,727        3,939,575 
Total Liabilities and Stockholders’ Equity  $3,901,678   $1,573,895       $5,475,573 

  

2

 

 

ADIAL PHARMACEUTICALS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended March 31, 2023

 

       Pro Forma       
   Historical   Adjustments     Pro Forma 
Operating Expenses:                 
Research and development expenses  $676,435   $(310,819) (o)  $365,616 
General and administrative expenses   2,244,293    (341,134) (o)   1,903,159 
Total Operating Expenses   2,920,728    (651,953)     2,268,775 
                  
Loss From Operations   (2,920,728)   651,953      (2,268,775)
                  
Other Income (Expense)                 
Change in value of contingent liability   (14,000)   14,000  (p)   — 
Interest income   28,892    —      28,892 
Total other income (expense)   14,892    14,000      28,892 
                  
Income (Loss) Before Provision For Income Taxes   (2,905,836)   665,953      (2,239,883)
Provision for income taxes   —    —      — 
Loss from continuing operations  $(2,905,836)  $665,953     $(2,239,883)
Net Loss   (2,905,836)   665,953      (2,239,883)
                  
Net loss per share, basic and diluted  $(2.75)  $0.63     $(2.12)
                  
Weighted average shares, basic and diluted   1,058,542    1,058,542      1,058,542 

 

ADIAL PHARMACEUTICALS, INC.

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Year Ended December 31, 2022

 

       Pro Forma       
   Historical   Adjustments     Pro Forma 
Operating Expenses:                 
Research and development expenses  $4,176,998   $(2,226,690) (q)  $1,950,308 
General and administrative expenses   9,140,129    (230,569) (q)   8,909,560 
Total Operating Expenses   13,317,127    (2,457,259)     10,859,868 
                  
Loss From Operations   (13,317,127)   2,457,259      (10,859,868)
                  
Other Income (Expense)                 
Change in value of contingent liability   522,000    (522,000) (r)   — 
Interest income   63,209    —      63,209 
Total other income (expense)   585,209    (522,000)     63,209 
                  
Income (Loss) Before Provision For Income Taxes   (12,731,918)   1,935,259      (10,796,659)
Provision for income taxes   502    —      502 
Loss from continuing operations   (12,731,416)   1,935,259      (10,796,157)
Income from discontinued operations, net of taxes   —    2,045,858  (s)   2,045,858 
Net Loss  $(12,731,416)  $3,981,117     $(8,750,229)
                  
Net loss per share, basic and diluted  $(12.71)  $3.98     $(8.74)
                  
Weighted average shares, basic and diluted   1,001,505    1,001,505      1,001,505 

 

3

 

 

ADIAL PHARMACEUTICALS

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS

 

Description of Transaction and Basis of Presentation

 

The unaudited pro forma condensed consolidated balance sheet and statements of operations are based upon the historical consolidated financial statements of Adial Pharmaceuticals, Inc. (the “Company”), which were included in its Quarterly Report on Form 10-Q for the three months ended March 31, 2023 and its Annual Report on Form 10-K for the year ended December 31, 2023. Unless the context indicates otherwise, any reference in this report to the “Company,” “we,” “us,” and “our” refers to Adial Pharmaceuticals, Inc.

 

On January 27, 2023, we executed an option agreement with Adovate, LLC (then Adenomed, LLC) (“Adovate”) which gave Adovate an option to purchase the business of the company’s wholly owned subsidiary, Purnovate, Inc. Adovate is a related party, the CEO, founder, and majority equity holder of Adovate being our former CEO and a current director. On exercise of the option, Adovate would acquire the business of Purnovate, including: (1) the rights to Purnovate’s lead drug candidate, along with any associated intellectual property, trade secrets, and know-how; (2) the transfer and benefit of all Purnovate vendor contracts and its operating lease, including prepayments and deposits; (3) all property and equipment of Purnovate; and (4) the rest of Purnovate’s business, including any intellectual property, trade secrets, or know-how. Consideration due on the exercise of the option were: (i) upfront cash payments totaling $450,000 upon the Option exercise; (ii) the issuance by Buyer to Company of 19.9% of the equity of Buyer; (iii) the assumption by Buyer of contingent payments due the former shareholders of Purnovate, Inc.; (iv) the assumption by Buyer of the obligations of Company to contracted Purnovate employees; (v) low, single digit royalty payments on net sales of all Purnovate products; (vi) contingent cash payments of up to approximately $11 million based on the achievement in development and approval milestones for each Purnovate compound to reach the milestones after payments to the prior members of Purnovate pursuant to the Company’s previous agreement with the prior members of Purnovate for the Purchase of Purnovate; (vii) contingent cash payments of up to an aggregate of $50,000,000 upon the achievement of certain commercial milestones by the buyer; and (viii) cash reimbursement of Purnovate expenses incurred and paid from Dec. 1, 2022 to the option exercise date of May 16, 2023. The Buyer also assumed operating liabilities of Purnovate, including: (ix) trade payables incurred for services or purchases by Purnovate exclusively for its research operations; and (x) the lease for 1180 Seminole Trail, Suite 495, Charlottesville, VA 22901.

 

On May 8, 2023, Adovate sent a letter exercising its option effective May 16, 2023 and made payment of the $450,000 in fees due on exercise. On June 30, 2023, Adovate issued to us the equity due under the option exercise and we executed documents confirming the transfer of Purnovate’s business as described above, completing the sale. The unaudited pro forma condensed consolidated statements of operations reflect the sale by the Company of the business of the Company’s wholly owned subsidiary, Purnovate, Inc., as if the sale had been consummated on January 1, 2022 (the first day of our 2022 fiscal year). The unaudited pro forma condensed consolidated balance sheet as of March 31, 2023 reflect such sale as if it had been consummated on that date.

 

Pro Forma Adjustments

 

Effective as of June 30, 2023 the Company completed the sale by the Company of the business of the Company’s wholly owned subsidiary, Purnovate, Inc. pursuant to the terms of an Option Agreement (the “Agreement”) dated as of January 27, 2023.

 

The following pro forma adjustments are included in the unaudited pro forma condensed consolidated balance sheet and/or the unaudited pro forma condensed consolidated statements of operations:

 

(a) Reflects the $150,000 option exercise fee and upfront payment of $300,000 due on exercise and paid on May 8, 2023, as described in (i) above.
   
(b) Deposits and prepaid expenses associated with vendor contracts which were transferred to the buyer on option exercise, as described in (2) above, at the values of these assets had buyer exercised its option on March 31, 2023.
   
(c) Reflects reimbursements of expenses due from buyer from December 1, 2022 to the option exercise date, as described in (viii) above, based on total reimbursable expenses had buyer exercised its option on March 31, 2023.
   
(d) Fixed assets, net of accumulated depreciation, including lab and office equipment and furnishings, which were transferred to Purnovate, as described in (3) above, with net of these assets on March 31, 2023.

 

4

 

 

(e) The rights to Purnovate’s ongoing lead drug development program, as described in (1) above.
   
(f) Right-to-use asset associated with lease transferred on option exercise, as described in (2) above, the value of the asset as it was on March 31, 2023.
   
(g) Goodwill of business of Purnovate sold, reflecting the rights in to all other Purnovate drug development programs, know-how, and the rest of its business, as described in (3) above.
   
(h) Fair value of equity issued in the buyer of Purnovate to Company in consideration of sale, due on option exercise, had the equity been issued on March 31, 2023.
   
(i) Accounts payable associated with transferred vendor contracts which were transferred to the buyer, as described in (ix) above, at the amount of the liabilities had buyer exercised its option on March 31, 2023.
   
(j) Accrued expenses associated with vendor contracts which were transferred to the buyer, as described in (ix) above, at the amount of the liabilities had buyer exercised its option on March 31, 2023.
   
(k) Liability associated with lease assumed by the buyer, as described in (x) above, at amount of the liability had the Buyer exercised its option on March 31, 2023.
   
(l) Contingent liability to former Purnovate shareholders assumed by the buyer, as described in (iii) above, at the amount of liability on March 31, 2023.
   
(m) Deferred tax liability which arose as a result of the acquisition of Purnovate.
   
(n) Gain on exercise of option, had buyer exercised its option on March 31, 2023.
   
(o) Reversal of expenses attributable to Purnovate operations in the three months ended March 31, 2023, which included the costs of Purnovate research and development activities, the wages salaries of Purnovate employees, the cost of the transferred lease, depreciation of the transferred equipment, and fees to Purnovate contractors.
   
(p) Reversal of expense due to net increase of the contingent consideration liability to former Purnovate shareholders in the three months ended March 31, 2023, which was assumed by the buyer on option exercise as described in (iii) above, had the option been exercised January 1, 2022.
   
(q) Reversal of expenses attributable to Purnovate operations in the year ended December 31, 2022, which included the costs of Purnovate research and development activities, the wages salaries of Purnovate employees, the cost of the transferred lease, depreciation of the transferred equipment, and fees to Purnovate contractors.
   
(r) Reversal of gain due to net increase of the contingent consideration liability to former Purnovate shareholders in the year ended December 31, 2022, which was assumed by the buyer on option exercise as described in (iii) above, had the option been exercised January 1, 2022.
   
(s) Gain on exercise of option, had buyer exercised its option on January 1, 2022.

 

 

5

 

 

 EX-101.SCH 3 adil-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 adil-20230630_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 adil-20230630_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Jun. 30, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 30, 2023
Entity File Number 001-38323
Entity Registrant Name Adial Pharmaceuticals, Inc.
Entity Central Index Key 0001513525
Entity Tax Identification Number 82-3074668
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1180 Seminole Trail
Entity Address, Address Line Two Ste 495
Entity Address, City or Town Charlottesville
Entity Address, State or Province VA
Entity Address, Postal Zip Code 22901
City Area Code 434
Local Phone Number 422-9800
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol ADIL
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 ea183898-8k_adialpharm_htm.xml IDEA: XBRL DOCUMENT 0001513525 2023-06-30 2023-06-30 iso4217:USD shares iso4217:USD shares 0001513525 false 8-K 2023-06-30 Adial Pharmaceuticals, Inc. DE 001-38323 82-3074668 1180 Seminole Trail Ste 495 Charlottesville VA 22901 434 422-9800 false false false false Common Stock ADIL NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adialpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea183898-8k_adialpharm.htm adil-20230630.xsd adil-20230630_lab.xml adil-20230630_pre.xml ea183898ex99-1_adialpharm.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea183898-8k_adialpharm.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "ea183898-8k_adialpharm.htm" ] }, "labelLink": { "local": [ "adil-20230630_lab.xml" ] }, "presentationLink": { "local": [ "adil-20230630_pre.xml" ] }, "schema": { "local": [ "adil-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ADIL", "nsuri": "http://adialpharma.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea183898-8k_adialpharm.htm", "contextRef": "AsOf2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://adialpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea183898-8k_adialpharm.htm", "contextRef": "AsOf2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://adialpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001213900-23-069028-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-23-069028-xbrl.zip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end